To view enhanced content for this article go to http://www.medengine.com/Redeem/0AF8F060651D636A.
Bromfenac is a well-known topical ophthalmic nonsteroidal anti-inflammatory drug (NSAID) that is commercialized in the USA and other regions of the world. A new formulation, 0.075% bromfenac in DuraSite®, was developed to treat postoperative inflammation and reduce pain in patients who have undergone cataract surgery. We hypothesized that efficacy and safety would be enhanced with twice-daily (BID) dosing compared to once-daily (QD) dosing.
This was a multicenter, double-masked, comparative study in which 40 and 45 subjects were randomized to groups receiving BID dosing and QD dosing, respectively. Subjects self-instilled the study drug for 14 days postoperative and were followed for an additional 2-week evaluation phase. The primary efficacy endpoint was the proportion of subjects with an anterior chamber cell (ACC) grade of 0 at day 15.
A total of 45 subjects had cleared ACC (grade “0”) at day 15, of whom 21 were in the BID group (52.5%) and 24 were in the QD group (53.5%). A secondary analysis found 7/40 (17.5%) subjects in the BID group and 10/45 (22.2%) subjects in the QD group achieved an ACC grade of 0 at day 8. There were more adverse events in the QD group (n = 16) than in the BID group (n = 12).
Similar outcomes were observed for subjects using Bromfenac 0.075% in DuraSite® in the BID and QD dosing regimens for the treatment of post-cataract surgery inflammation.
ClinicalTrials.gov identifier, NCT01190878.
InSite Vision (now a division of Sun Pharma).
Senju Pharmaceutical Co. Bronuck (package insert). Senju Pharmaceutical Co., Osaka, 2009.
ISTA Pharmaceuticals. Xibrom (package insert). ISTA Pharmaceuticals, Irvine, 2010.
ISTA Pharmaceuticals. Bromday (package insert). ISTA Pharmaceuticals, Irvine, 2011.
Committee for Medicinal Products for Human Use (CHMP). Yellox Assessment Report. Report No.: EMA/431843/2011. European Medicines Agency, London, 2011.
InSite Vision. BromSite (prescribing information). InSite Vision, Alameda, 2016.
Hosseini K, Hutcheson J, Bowman LM. Aqueous humor concentration of Bromfenac 0.09% (Bromday) compared with Bromfenac in DuraSite 0.075% (Bromsite) in cataract patients undergoing phacoemulsification after 3 days dosing. Association for Research in Vision and Ophthalmology. Seattle, 2013.
Tsai T, Kroehl M, Smith S, et al. Efficacy and safety of twice- versus once-daily dosing of lisinopril for the treatment of hypertension. In: 50th Midyear meeting of the American Society of Health-System Pharmacists. New Orleans, LA, 2015.
- Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II